Leave a request
Merck confirmed an agreement with UNICEF to establish the world’s first global Ebola vaccine stockpile with ERVEBO® (Ebola Zaire Vaccine, Live).
This agreement represents another landmark milestone in the fight against Ebola and is the result of breakthrough innovation and collaboration across Africa and the world. ERVEBO is a vaccine indicated for the prevention of disease caused by Zaire ebolavirus in individuals 18 years of age and older. The duration of protection conferred by ERVEBO is unknown. ERVEBO does not protect against other species of Ebolavirus or Marburgvirus.
Effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (IG), and/or blood or plasma transfusions is unknown. Do not administer ERVEBO to individuals with a history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including rice protein.
The global stockpile will offer a critical, rapid-response tool to help combat future outbreaks of this highly contagious, hemorrhagic illness that is endemic in parts of Central and West Africa. The stockpile inventory will be built over time and maintained by Merck. To ensure equitable and public health risk-based use of the vaccine, the stockpile will be governed by the International Coordinating Group (ICG) on Vaccine Provision in accordance with guidance from the Strategic Advisory Group of Experts (SAGE) on immunization.
By Аvera Allen | Linkedin
#News #Health #Medical #Merck #Whealthnews
Leave a request